CRBP stock icon

Corbus Pharmaceuticals
CRBP

$53.34
3.52%
 

About: Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Employees: 19

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 9 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

7,291% more capital invested

Capital invested by funds: $4.53M [Q4 2023] → $335M (+$330M) [Q1 2024]

920% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 5

300% more funds holding in top 10

Funds holding in top 10: 0 [Q4 2023] → 3 (+3) [Q1 2024]

150% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 6

135% more funds holding

Funds holding: 34 [Q4 2023] → 80 (+46) [Q1 2024]

64.35% more ownership

Funds ownership: 16.96% [Q4 2023] → 81.31% (+64.35%) [Q1 2024]

3% more call options, than puts

Call options by funds: $3.2M | Put options by funds: $3.09M

Research analyst outlook

9 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$46
14%
downside
Avg. target
$69
29%
upside
High target
$85
59%
upside

9 analyst ratings

positive
100%
neutral
0%
negative
0%
Oppenheimer
Jeff Jones
50%upside
$80
Outperform
Reiterated
10 Jul 2024
B. Riley Securities
Kalpit Patel
59%upside
$85
Buy
Initiated
26 Jun 2024
RBC Capital
Brian Abrahams
54%upside
$82
Outperform
Maintained
11 Jun 2024
Oppenheimer
Jeff Jones
50%upside
$80
Outperform
Maintained
3 Jun 2024
RBC Capital
Brian Abrahams
44%upside
$77
Outperform
Initiated
13 May 2024

Financial journalist opinion